VYGR - Voyager Therapeutics, Inc.

QQQ $ 474.86 $ 2.12 (0.45 %)

DIA $ 414.87 $ 2.97 (0.72 %)

SPY $ 561.82 $ 2.92 (0.52 %)

TLT $ 100.40 $ 0.27 (0.27 %)

GLD $ 238.66 $ 2.35 (0.99 %)

Previous Close

$ 6.25

Open

$ 6.26

Bid

$ 6.23 x 1,094

Ask

-- x --

Day's Range

$ 6.14 - $ 6.30

52 Week Range

$ 5.97 - $ 11.72

Volume

471,604

Average Volume

Market Cap

340.83M

Beta (5Y Monthly)

$ 1.29

PE Ratio (TTM)

$ 37.77

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-13-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-07-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	03-08-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	03-03-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-09-2019	06-30-2019	10-Q
22	05-07-2019	03-31-2019	10-Q
23	02-26-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	03-14-2018	12-31-2017	10-K
28	11-02-2017	09-30-2017	10-Q
29	08-08-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	03-15-2017	12-31-2016	10-K
32	11-10-2016	09-30-2016	10-Q
33	08-11-2016	06-30-2016	10-Q
34	05-12-2016	03-31-2016	10-Q
35	03-17-2016	12-31-2015	10-K
36	12-17-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Voyager Therapeutics Announces Novartis Li...
09/05/2024 12:04:45

HC Wainwright & Co. Reiterates Buy on Voya...
08/20/2024 10:30:26

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

Wedbush Maintains Neutral on Voyager Thera...
08/07/2024 13:50:15

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $8 ...

Voyager Therapeutics Q2 2024 GAAP EPS $(0....
08/06/2024 20:10:40

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...

What Analysts Are Saying About Voyager The...
07/31/2024 13:00:50

HC Wainwright & Co. Reiterates Buy on Voya...
07/31/2024 12:12:46

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

Voyager Therapeutics Taps Nathan Jorgensen...
06/13/2024 11:20:10

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announc...

HC Wainwright & Co. Reiterates Buy on Voya...
05/16/2024 17:30:02

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

Voyager Therapeutics Says First Participan...
05/16/2024 11:15:03

Oppenheimer Maintains Outperform on Voyage...
05/15/2024 15:40:19

Oppenheimer analyst Jay Olson maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and maintains $18 price target.

Wedbush Maintains Neutral on Voyager Thera...
05/14/2024 12:32:23

Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $10...

Voyager Therapeutics Reports Cash Position...
05/13/2024 20:04:37

Voyager Therapeutics Q1 2024 GAAP EPS $(0....
05/13/2024 20:02:41

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of ...

Voyager Therapeutics Presents Data for Sec...
05/08/2024 10:12:34

Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple...

Voyager Therapeutics To Present Translatio...
04/22/2024 20:31:45

Selection Of The Development Candidate Tri...
04/16/2024 11:12:24

Voyager Therapeutics And Neurocrine Biosci...
04/16/2024 11:07:51

Voyager Therapeutics And Neurocrine Biosci...
04/16/2024 11:06:21

Voyager Therapeutics Said Co And CFO Peter...
04/02/2024 20:36:35

-8-K

Guggenheim Initiates Coverage On Voyager T...
03/26/2024 10:39:06

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with a Buy rating and annou...